Revenue Growth and Recurring Streams
The company delivered a 95% sequential revenue increase in Q3, driven by expanding recurring revenue streams and deeper customer engagement, marking a decisive turning point.
SteraMist IHP Technology Recognition
TOMI's SteraMist IHP technology was named Disinfection and Decontamination Products Company of the Year 2025, indicating industry recognition and validation for their technology.
Active Pipeline and Backlog Expansion
Sales order backlog grew to $1.3 million by October 31, with approximately $3 million in pending integration contracts and an active pipeline surpassing $15 million.
Regulatory Approvals and New Market Entries
FDA's broadened approval of hydrogen peroxide positions TOMI to enter agriculture, food processing, and environmental biosafety markets.
Strategic Milestones and Capital Flexibility
TOMI entered an equity purchase agreement with Hudson Global Ventures, providing the right to sell up to $20 million in common stock, offering capital flexibility.